Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is...
5 insider purchases on record · latest filing 2024-03-28.
Insiders have also filed 18 sale transactions at SGMT.